MindBio Therapeutics Corp. (CSE: MBIO) (OTCQB: MBQIF) has taken steps to solidify its intellectual property in the field of AI-driven intoxication detection, filing patent applications covering 15 novel discoveries that link speech patterns to impairment from drugs and alcohol. The company announced the filings in a recent update, highlighting a machine learning model that analyzes short voice samples to estimate intoxication levels without requiring physical samples such as blood, urine, or breath.
The technology is designed for high-volume, regulated environments where traditional testing is costly and time-consuming. MindBio’s initial commercial rollout targets the mining and aviation industries through Edge AI kiosk systems, which can process voice samples on-site without cloud connectivity. The company also sees broader applications in call centers, law enforcement, and mental health screening, where non-invasive impairment detection could improve safety and compliance.
The global drug and alcohol testing market is projected to reach $4.2 billion by 2033, according to industry forecasts. MindBio’s approach leverages voice biometrics and machine learning to detect subtle changes in speech caused by substances, potentially offering a faster and less intrusive alternative to existing methods. The patent filings cover 15 distinct discoveries made during the development of the platform, though specific technical details have not been disclosed.
MindBio Therapeutics is a biotechnology company focused on commercializing AI-driven voice technology for intoxication detection. The company’s shares trade on the Canadian Securities Exchange under the symbol MBIO and on the OTCQB under MBQIF. Further information about the company’s news and updates is available in its newsroom at https://ibn.fm/MBQIF.
InvestorWire, the platform that disseminated this announcement, is a communications service specializing in press release syndication for public and private companies. It is part of the Dynamic Brand Portfolio @ IBN, which offers wire solutions, editorial syndication to over 5,000 outlets, press release enhancement, social media distribution, and corporate communications services. InvestorWire is based in Austin, Texas, and can be reached through its website at https://www.InvestorWire.com. Full terms of use and disclaimers are available on the InvestorWire website at https://www.InvestorWire.com/Disclaimer.
The patent filings represent a strategic move by MindBio to protect its innovations in a competitive market. By targeting industries with stringent safety requirements, the company aims to establish a foothold for voice-based testing as a scalable solution. If successful, the technology could reshape how employers and regulators monitor impairment, reducing reliance on biological samples and enabling real-time screening in field settings.
This news story relied on content distributed by InvestorBrandNetwork (IBN). Blockchain Registration, Verification & Enhancement provided by NewsRamp™. The source URL for this press release is MindBio Therapeutics Files Patents for AI Voice-Based Intoxication Detection, Targets Mining and Aviation.